BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/16/2022 3:57:03 PM | Browse: 359 | Download: 1310
 |
Received |
|
2021-10-11 17:21 |
|
Peer-Review Started |
|
2021-10-11 17:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-06 06:05 |
|
Revised |
|
2021-12-14 16:30 |
|
Second Decision |
|
2022-02-15 03:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-02-16 07:27 |
|
Articles in Press |
|
2022-02-16 07:27 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-02-11 21:31 |
|
Typeset the Manuscript |
|
2022-03-10 16:40 |
|
Publish the Manuscript Online |
|
2022-03-16 15:57 |
| ISSN |
1948-5190 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Clara Benedetta Conti, Elsa Mainardi, Sara Soro, Sophie Testa, Annalisa De Silvestri, Andrea Drago, Fabrizio Cereatti and Roberto Grassia |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Clara Benedetta Conti, MD, Consultant Physician-Scientist, Gastroenterology and Digestive Endoscopy, ASST Cremona, Viale Concordia 1, Cremona 26100, Italy. benedetta.conti1@gmail.com |
| Key Words |
Inflammatory bowel disease; SARS-CoV-2; COVID-19; Biologic treatment; SARS-CoV-2 antibody; Inflammatory bowel disease therapy |
| Core Tip |
Guidelines recommend ceasing inflammatory bowel disease (IBD) biologic therapy during coronavirus disease 2019 (COVID-19). IBD patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 IgG. In total, 103 IBD patients were enrolled. We found that 18.4% had IgG positivity, and 63% developed COVID-19 disease with symptoms. However, all but one patient with symptoms did not require ceasing IBD treatment no hospitalization. None of the patients under biologic therapy developed severe COVID-19. Therefore, the IBD population does not seem to have a high risk of severe COVID-19, particularly if under biological treatment or mesalazine. |
| Publish Date |
2022-03-16 15:57 |
| Citation |
Conti CB, Mainardi E, Soro S, Testa S, De Silvestri A, Drago A, Cereatti F, Grassia R. SARS-CoV-2 in inflammatory bowel diseases population: Antibodies, disease and correlation with therapy. World J Gastrointest Endosc 2022; 14(3): 153-162 |
| URL |
https://www.wjgnet.com/1948-5190/full/v14/i3/153.htm |
| DOI |
https://dx.doi.org/10.4253/wjge.v14.i3.153 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
